Earnings Summary: Organon reports financial results for Q4 2023

Watch Icon
AlphaStreet

Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.

Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currencyWomen’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility productsBiosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in ChinaQ4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last yearAt $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.

The post Earnings Summary: Organon reports financial results for Q4 2023 first appeared on AlphaStreet.